Execs On The Move: C-Suite Changes at Nuvectra, Biogennix, Microbot
An experienced board member steps up to fill the CEO slot at neurostim firm Nuvectra; a new CFO is taken on board at osteobiological products company Biogennix; and Microbot Medical's chief operating officer resigns.
You may also be interested in...
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.